EUVIMEDEUVIMED entdecken
Crossref

Efficacy of generic forms of itraconazole capsule in treating subjects with chronic pulmonary aspergillosis

Inderpaul Singh Sehgal iD, Keshavamurthy Vinay, Sahajal Dhooria, Valliappan Muthu iD, Kuruswamy Thurai Prasad, Ashutosh Nath Aggarwal, Arunaloke Chakrabarti, Shivaprakash M Rudramurthy iD, Hansraj Choudhary, Ritesh Agarwal iD

Mycoses · 2023-07 · 66 (7) · 576-584

DOI: 10.1111/myc.13583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mycoses, online erschienen am 26.03.2023. Verfasst von Inderpaul Singh Sehgal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Itraconazole, Pulmonary Aspergillosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Itraconazole capsules have variable and unpredictable bioavailability.

Objective

Whether the generic brands are as effective as the innovator itraconazole in treating subjects with chronic pulmonary aspergillosis (CPA) remains unclear.

Methods

In this retrospective study, we treated CPA subjects with 6‐month itraconazole capsule and measured itraconazole levels at 2 weeks, 3 months and 6 months. Our primary outcome was to compare the proportion of subjects achieving therapeutic drug levels (≥0.5 mg/L) with the generic and the innovator itraconazole after 2 weeks. We performed a multivariate logistic regression analysis to ascertain whether trough itraconazole levels affected treatment outcomes. We categorised treatment response as favourable or unfavourable based on improvement (or worsening) in clinical symptoms, microbiology and imaging. We also performed morphometric analysis of different brands of itraconazole by video‐dermoscopy.

Results

We included 193 (generic brands [ n = 94] and innovator itraconazole [ n = 99]) CPA subjects. A higher proportion of subjects achieved therapeutic levels at 2 weeks with the innovator than with the generic brands (72/99 [73%] vs. 27/94 [29%], p < .0001). The median trough level at 2 weeks was higher with the innovator than the generic brands (0.8 vs. 0 mg/L). The mean trough itraconazole levels achieved (average of three values measured over 6 months) independently predicted a favourable treatment response after adjusting for age, gender and CPA severity. On morphometric analysis, the generic brands had variable pellet numbers and sizes, and dummy pellets.

Conclusion

At 2 weeks, a significantly higher proportion of CPA subjects achieved therapeutic drug levels with the innovator than the generic itraconazole. The mean serum itraconazole levels independently predicted a favourable treatment response in CPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ItraconazolePulmonary AspergillosisHumansAntifungal AgentsRetrospective StudiesTreatment OutcomePersistent Infection

Stichwörter der Autor:innen

CPAaspergillosisitraconazoleoral azolessimple aspergilloma

Substanzen

ItraconazoleAntifungal Agents

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Doodhadhari Burfani Hospital, Haridwar, Uttarakhand, India.
  • Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

ORCID-Profile: Inderpaul Singh Sehgal, Valliappan Muthu, Shivaprakash M Rudramurthy, Ritesh Agarwal

Zitieren

APA

Sehgal, I. S., Vinay, K., Dhooria, S., Muthu, V., Prasad, K. T., Aggarwal, A. N., Chakrabarti, A., Rudramurthy, S. M., Choudhary, H., & Agarwal, R. (2023). Efficacy of generic forms of itraconazole capsule in treating subjects with chronic pulmonary aspergillosis. Mycoses, 66(7), 576-584. https://doi.org/10.1111/myc.13583

Vancouver

Sehgal IS, Vinay K, Dhooria S, Muthu V, Prasad KT, Aggarwal AN, et al. Efficacy of generic forms of itraconazole capsule in treating subjects with chronic pulmonary aspergillosis. Mycoses. 2023;66(7):576-584. doi:10.1111/myc.13583

BibTeX
@article{Sehgal2023,
  author = {Sehgal, Inderpaul Singh and Vinay, Keshavamurthy and Dhooria, Sahajal and Muthu, Valliappan and Prasad, Kuruswamy Thurai and Aggarwal, Ashutosh Nath and Chakrabarti, Arunaloke and Rudramurthy, Shivaprakash M and Choudhary, Hansraj and Agarwal, Ritesh},
  title = {Efficacy of generic forms of itraconazole capsule in treating subjects with chronic pulmonary aspergillosis},
  journal = {Mycoses},
  year = {2023},
  volume = {66},
  number = {7},
  pages = {576--584},
  doi = {10.1111/myc.13583}
}
Kostenlos starten →